We update our weekly tracker of the US IV generic market, focusing on sales and volumes for individual companies and the overall market, as well as providing analysis of individual products, which shows continued strong momentum for Kabi into August.
For the market overall, we observe a sequentially softer weekly print following a strong IV sales development in July, despite an easier comp. US generic injectable sales saw a modest c.+2% y/y in w/e August 4 (vs....